Endometrial Mesonephric-like Carcinosarcoma With Shared KRAS, TP53, and RB1 Mutations: Report of a Rare Case Highlighting Diagnostic Challenges and Novel Molecular Insights, and Review of the Literature
Authors:
- Zitong ZhaoZZZitong Zhao
- Timothy Kwang Yong TayTTTimothy Kwang Yong Tay
- Tony Kiat Hon LimTLTony Kiat Hon Lim
- Liang Seah TayLTLiang Seah Tay
- Gek San TanGTGek San Tan
- Wui Seng KhooWKWui Seng Khoo
- Inny BusmanisIBInny Busmanis
- Shing Lih WongSWShing Lih Wong
- 3 July 2026
- journal article
- review article
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
Abstract
Mesonephric-like carcinosarcoma (MLCS) is an uncommon gynecologic malignancy comprising mesonephric-like adenocarcinomatous (MLA) and high-grade (HG) sarcomatous elements. We describe an endometrial MLCS in a 63-yr-old woman showing divergent p53 immunohistochemical expression, with abnormal expression in the MLA component and normal expression in the sarcomatous component. Dedifferentiated carcinoma and uterine mesenchymal tumors are primary differential diagnoses when sarcomatous elements predominate or exhibit round-cell morphology. A review of 25 endometrial MLCS cases, including ours, showed advanced-stage presentation in 48% (12/25), recurrence in 60% (15/25) and disease-related death in 28% (7/25) of cases, underscoring its aggressive behavior. Heterologous differentiation occurred in 16% of cases but was not essential for diagnosis when unequivocal HG sarcomatous cells were present. Component-specific next-generation sequencing of our case revealed identical KRAS , TP53 , and RB1 mutations in both components, with additional PTPRT mutation and KLF5 amplification restricted to the MLA component, representing a novel molecular signature with potential therapeutic implications.Keywords
This publication has 20 references indexed in Scilit:
- Molecular Landscape of TP53 / RB1 Co‐Altered Tumors Uncovers Emerging Therapeutic VulnerabilitiesGenes, Chromosomes and Cancer, 2026
- Endometrial carcinomas with ambiguous histology often harbor TP53 mutationsVirchows Archiv, 2024
- Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastasesLaboratory Investigation, 2021
- Next generation sequencing is informing phenotype: a TP53 exampleFamilial Cancer, 2017
- Integrated Molecular Characterization of Uterine CarcinosarcomaCancer Cell, 2017
- Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinomaThe Journal of Pathology: Clinical Research, 2016
- Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tractLaboratory Investigation, 2015
- Endometrial carcinomas with ambiguous featuresSeminars in Diagnostic Pathology, 2010
- Evaluation of the molecular mechanisms involved in the gain of function of a Li-FraumeniTP53 MutationHuman Mutation, 2005
- Malignant Mesonephric Tumors of the Female Genital TractAmerican Journal of Surgical Pathology, 2004